<div id="readability-page-1"><p><span>Verastem (NASDAQ:VSTM - Get Free Report)</span> had its price target reduced by equities research analysts at Royal Bank of Canada  from $16.00 to $14.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an &#34;outperform&#34; rating on the biopharmaceutical company's stock. Royal Bank of Canada's price target suggests a potential upside of 109.74% from the stock's previous close.</p><p>Several other research firms have also issued reports on VSTM. HC Wainwright  reiterated a &#34;buy&#34; rating and issued a $7.00 target price on shares of Verastem in a research note on Thursday, December 19th. Guggenheim  reiterated a &#34;buy&#34; rating on shares of Verastem in a research note on Friday, January 24th. BTIG Research raised their target price on shares of Verastem from $13.00 to $20.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, December 31st. Mizuho upped their price target on Verastem from $7.00 to $9.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, December 19th. Finally, B. Riley increased their price objective on Verastem from $7.00 to $9.00 and gave the company a &#34;buy&#34; rating in a report on Friday, January 31st. One analyst  has rated the stock with a sell rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $13.38.</p><p><b>Read Our Latest Report on Verastem</b></p><h2>Verastem Stock Down 2.1 %</h2><p>Shares of VSTM stock traded down $0.15 on Friday, hitting $6.68. The stock had a trading volume of 471,304 shares, compared to its average volume of 908,010. Verastem has a one year low of $2.10 and a one year high of $13.52. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 2.77. The company has a market cap of $297.08 million, a PE ratio of -2.09 and a beta of 0.60. The business has a 50 day moving average price of $6.00 and a 200 day moving average price of $4.58. </p><p>Verastem (NASDAQ:VSTM - Get Free Report) last issued its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.57).  Research analysts anticipate that  Verastem will post -3.02 earnings per share for the current fiscal year. </p><h2>Insider Buying and Selling at Verastem</h2><p>In other news, CEO Dan Paterson sold 8,568 shares of the company's stock in a transaction on Monday, January 13th. The shares were sold at an average price of $5.24, for a total value of $44,896.32. Following the sale, the chief executive officer now directly owns 347,581 shares of the company's stock, valued at $1,821,324.44. This represents a 2.41 % decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders have sold 9,988 shares of company stock worth $53,608. 2.20% of the stock is currently owned by insiders. </p><h2>Institutional Inflows and Outflows</h2><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in VSTM. Walleye Capital LLC raised its stake in shares of  Verastem by 493.7% during the 3rd quarter. Walleye Capital LLC now owns 216,126 shares of the biopharmaceutical company's stock valued at $646,000 after buying an additional 179,725 shares during the last quarter.  Geode Capital Management LLC grew its holdings in  Verastem by 67.6% during the third quarter. Geode Capital Management LLC now owns 890,599 shares of the biopharmaceutical company's stock worth $2,663,000 after acquiring an additional 359,060 shares during the period.  Rhumbline Advisers raised its position in  Verastem by 38.0% during the fourth quarter. Rhumbline Advisers now owns 37,629 shares of the biopharmaceutical company's stock valued at $195,000 after acquiring an additional 10,352 shares in the last quarter.  Barclays PLC lifted its holdings in  Verastem by 546.7% in the third quarter. Barclays PLC now owns 55,708 shares of the biopharmaceutical company's stock valued at $167,000 after acquiring an additional 47,094 shares during the period.  Finally, XTX Topco Ltd acquired a new stake in  Verastem during the third quarter valued at $112,000. 88.37% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Verastem Company Profile</h2> (Get Free Report)<p>Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Verastem</li><li>How to Calculate Options Profits</li><li>FedEx Delivers Another Crushing Blow to Its Stock Price</li><li>What Does a Stock Split Mean? </li><li>Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge</li><li>Transportation Stocks Investing</li><li>Micron Stock Will Retest All-Time Highs This Year</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlNUTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlNUTQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Verastem Right Now?</h2><p>Before you consider Verastem, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verastem wasn't on the list.</p><p>While Verastem currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VSTM

<p>Royal Bank of Canada has lowered its price target for Verastem (NASDAQ:VSTM) from $16.00 to $14.00 while maintaining an "outperform" rating. This suggests a potential upside of 109.74% from the stock's previous close. Other firms have varying ratings, with a consensus target price of $13.38. Verastem's stock recently traded down 2.1% to $6.68, with a market cap of $297.08 million. The company reported a quarterly EPS of ($1.33), missing estimates, and insiders have sold shares recently, indicating some activity in the stock.</p>

Royal Bank of Canada Has Lowered Expectations for Verastem (NASDAQ:VSTM) Stock Price